BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.
We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC’s (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.
Completing the Phase 1 clinical trial in China paves the way for Chinese sites to join the global BV100 Phase 3 RIV-TARGET trial by the end of 2026…
Read full press release here…
BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 2027…
BioVersys has signed a major global research collaboration with Shionogi & Co., Ltd. The partnership focuses on the joint development of novel antibiotics for non-tuberculous mycobacteria (NTM), with potential milestone payments of up to CHF 479 million.
BioVersys plans to conduct an initial public offering on the SIX Swiss Exchange in the first quarter of 2025.
| Building | C3 |
|---|---|
| Industry | Biotech |
| Research Topics | Antimicrobial Resistance (AMR) |
| Employees | 23 |
| Founding year | 2010 |
Home 
About us 
Offer 
News 
Financial support for start-ups in Basel 
Media 
Contact 